nodes	percent_of_prediction	percent_of_DWPC	metapath
Alosetron—CYP2C9—Capecitabine—esophageal cancer	0.0764	0.665	CbGbCtD
Alosetron—CYP2C9—Cisplatin—esophageal cancer	0.0385	0.335	CbGbCtD
Alosetron—Diuresis—Cisplatin—esophageal cancer	0.0164	0.0523	CcSEcCtD
Alosetron—HTR3A—vagus nerve—esophageal cancer	0.013	0.662	CbGeAlD
Alosetron—Balance disorder—Capecitabine—esophageal cancer	0.00684	0.0219	CcSEcCtD
Alosetron—Cognitive disorder—Methotrexate—esophageal cancer	0.00644	0.0206	CcSEcCtD
Alosetron—Haemorrhoids—Capecitabine—esophageal cancer	0.00636	0.0203	CcSEcCtD
Alosetron—Infection—Carboplatin—esophageal cancer	0.00613	0.0196	CcSEcCtD
Alosetron—Haematoma—Capecitabine—esophageal cancer	0.00595	0.019	CcSEcCtD
Alosetron—Tenderness—Cisplatin—esophageal cancer	0.00582	0.0186	CcSEcCtD
Alosetron—Nail disorder—Capecitabine—esophageal cancer	0.00577	0.0184	CcSEcCtD
Alosetron—Ulcer—Cisplatin—esophageal cancer	0.00537	0.0172	CcSEcCtD
Alosetron—Ileus—Capecitabine—esophageal cancer	0.00529	0.0169	CcSEcCtD
Alosetron—Pain—Carboplatin—esophageal cancer	0.00528	0.0169	CcSEcCtD
Alosetron—Laryngitis—Capecitabine—esophageal cancer	0.00519	0.0166	CcSEcCtD
Alosetron—Fungal infection—Capecitabine—esophageal cancer	0.00484	0.0155	CcSEcCtD
Alosetron—Extrasystoles—Capecitabine—esophageal cancer	0.00445	0.0142	CcSEcCtD
Alosetron—Folliculitis—Methotrexate—esophageal cancer	0.00443	0.0142	CcSEcCtD
Alosetron—Nail disorder—Methotrexate—esophageal cancer	0.00429	0.0137	CcSEcCtD
Alosetron—Contusion—Capecitabine—esophageal cancer	0.00429	0.0137	CcSEcCtD
Alosetron—Polyuria—Cisplatin—esophageal cancer	0.0042	0.0134	CcSEcCtD
Alosetron—Musculoskeletal stiffness—Capecitabine—esophageal cancer	0.00417	0.0133	CcSEcCtD
Alosetron—Burning sensation—Methotrexate—esophageal cancer	0.00401	0.0128	CcSEcCtD
Alosetron—Ulcer—Capecitabine—esophageal cancer	0.00395	0.0126	CcSEcCtD
Alosetron—Bone pain—Capecitabine—esophageal cancer	0.00391	0.0125	CcSEcCtD
Alosetron—Blood pressure increased—Capecitabine—esophageal cancer	0.00374	0.012	CcSEcCtD
Alosetron—Fungal infection—Methotrexate—esophageal cancer	0.00361	0.0115	CcSEcCtD
Alosetron—Colitis—Capecitabine—esophageal cancer	0.00359	0.0115	CcSEcCtD
Alosetron—Urine output increased—Capecitabine—esophageal cancer	0.00338	0.0108	CcSEcCtD
Alosetron—Cramp muscle—Cisplatin—esophageal cancer	0.00332	0.0106	CcSEcCtD
Alosetron—Nasopharyngitis—Cisplatin—esophageal cancer	0.00329	0.0105	CcSEcCtD
Alosetron—Sleep disorder—Capecitabine—esophageal cancer	0.00314	0.01	CcSEcCtD
Alosetron—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.0031	0.00992	CcSEcCtD
Alosetron—Polyuria—Capecitabine—esophageal cancer	0.00309	0.00989	CcSEcCtD
Alosetron—Gastroenteritis—Capecitabine—esophageal cancer	0.00306	0.00979	CcSEcCtD
Alosetron—Abdominal discomfort—Cisplatin—esophageal cancer	0.00305	0.00976	CcSEcCtD
Alosetron—Ulcer—Methotrexate—esophageal cancer	0.00294	0.00941	CcSEcCtD
Alosetron—Cystitis noninfective—Methotrexate—esophageal cancer	0.00272	0.00869	CcSEcCtD
Alosetron—Cystitis—Methotrexate—esophageal cancer	0.00269	0.0086	CcSEcCtD
Alosetron—Bladder pain—Methotrexate—esophageal cancer	0.00252	0.00805	CcSEcCtD
Alosetron—Urine output increased—Methotrexate—esophageal cancer	0.00252	0.00805	CcSEcCtD
Alosetron—Abdominal pain upper—Capecitabine—esophageal cancer	0.00248	0.00793	CcSEcCtD
Alosetron—Nasopharyngitis—Capecitabine—esophageal cancer	0.00243	0.00776	CcSEcCtD
Alosetron—Gastritis—Capecitabine—esophageal cancer	0.0024	0.00768	CcSEcCtD
Alosetron—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00239	0.00766	CcSEcCtD
Alosetron—Abdominal distension—Capecitabine—esophageal cancer	0.00236	0.00755	CcSEcCtD
Alosetron—Polyuria—Methotrexate—esophageal cancer	0.0023	0.00736	CcSEcCtD
Alosetron—Arrhythmia—Cisplatin—esophageal cancer	0.00228	0.00728	CcSEcCtD
Alosetron—Alopecia—Cisplatin—esophageal cancer	0.00225	0.0072	CcSEcCtD
Alosetron—Abdominal discomfort—Capecitabine—esophageal cancer	0.00225	0.00719	CcSEcCtD
Alosetron—Flatulence—Cisplatin—esophageal cancer	0.00219	0.00699	CcSEcCtD
Alosetron—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00218	0.00697	CcSEcCtD
Alosetron—Muscle spasms—Cisplatin—esophageal cancer	0.00213	0.00682	CcSEcCtD
Alosetron—Hyperglycaemia—Capecitabine—esophageal cancer	0.00212	0.00677	CcSEcCtD
Alosetron—Depression—Capecitabine—esophageal cancer	0.00209	0.00667	CcSEcCtD
Alosetron—Tremor—Cisplatin—esophageal cancer	0.00208	0.00664	CcSEcCtD
Alosetron—Ill-defined disorder—Cisplatin—esophageal cancer	0.00206	0.00658	CcSEcCtD
Alosetron—Jaundice—Capecitabine—esophageal cancer	0.00204	0.00652	CcSEcCtD
Alosetron—Urinary tract infection—Capecitabine—esophageal cancer	0.00203	0.0065	CcSEcCtD
Alosetron—Malaise—Cisplatin—esophageal cancer	0.002	0.00639	CcSEcCtD
Alosetron—Myalgia—Cisplatin—esophageal cancer	0.00189	0.00604	CcSEcCtD
Alosetron—Haemoglobin—Capecitabine—esophageal cancer	0.00189	0.00604	CcSEcCtD
Alosetron—Anxiety—Cisplatin—esophageal cancer	0.00188	0.00602	CcSEcCtD
Alosetron—Hepatitis—Capecitabine—esophageal cancer	0.00188	0.006	CcSEcCtD
Alosetron—Haemorrhage—Capecitabine—esophageal cancer	0.00188	0.006	CcSEcCtD
Alosetron—Hypoaesthesia—Capecitabine—esophageal cancer	0.00187	0.00597	CcSEcCtD
Alosetron—Discomfort—Cisplatin—esophageal cancer	0.00187	0.00596	CcSEcCtD
Alosetron—Infection—Cisplatin—esophageal cancer	0.0018	0.00575	CcSEcCtD
Alosetron—Skin disorder—Cisplatin—esophageal cancer	0.00176	0.00562	CcSEcCtD
Alosetron—Hyperhidrosis—Cisplatin—esophageal cancer	0.00175	0.00559	CcSEcCtD
Alosetron—Arrhythmia—Capecitabine—esophageal cancer	0.00168	0.00536	CcSEcCtD
Alosetron—Abdominal discomfort—Methotrexate—esophageal cancer	0.00167	0.00535	CcSEcCtD
Alosetron—Alopecia—Capecitabine—esophageal cancer	0.00166	0.00531	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00165	0.00527	CcSEcCtD
Alosetron—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00162	0.00519	CcSEcCtD
Alosetron—Flatulence—Capecitabine—esophageal cancer	0.00161	0.00515	CcSEcCtD
Alosetron—Muscle spasms—Capecitabine—esophageal cancer	0.00157	0.00503	CcSEcCtD
Alosetron—Depression—Methotrexate—esophageal cancer	0.00155	0.00497	CcSEcCtD
Alosetron—Pain—Cisplatin—esophageal cancer	0.00155	0.00495	CcSEcCtD
Alosetron—Tremor—Capecitabine—esophageal cancer	0.00153	0.0049	CcSEcCtD
Alosetron—Ill-defined disorder—Capecitabine—esophageal cancer	0.00152	0.00485	CcSEcCtD
Alosetron—Sweating—Methotrexate—esophageal cancer	0.00149	0.00477	CcSEcCtD
Alosetron—Feeling abnormal—Cisplatin—esophageal cancer	0.00149	0.00477	CcSEcCtD
Alosetron—HTR3A—digestive system—esophageal cancer	0.00148	0.0752	CbGeAlD
Alosetron—Malaise—Capecitabine—esophageal cancer	0.00147	0.00471	CcSEcCtD
Alosetron—Cough—Capecitabine—esophageal cancer	0.00143	0.00456	CcSEcCtD
Alosetron—Hypertension—Capecitabine—esophageal cancer	0.00141	0.00451	CcSEcCtD
Alosetron—Haemoglobin—Methotrexate—esophageal cancer	0.00141	0.00449	CcSEcCtD
Alosetron—Haemorrhage—Methotrexate—esophageal cancer	0.0014	0.00447	CcSEcCtD
Alosetron—Hepatitis—Methotrexate—esophageal cancer	0.0014	0.00447	CcSEcCtD
Alosetron—Myalgia—Capecitabine—esophageal cancer	0.00139	0.00445	CcSEcCtD
Alosetron—Anxiety—Capecitabine—esophageal cancer	0.00139	0.00443	CcSEcCtD
Alosetron—Discomfort—Capecitabine—esophageal cancer	0.00138	0.0044	CcSEcCtD
Alosetron—Dry mouth—Capecitabine—esophageal cancer	0.00136	0.00435	CcSEcCtD
Alosetron—Confusional state—Capecitabine—esophageal cancer	0.00135	0.0043	CcSEcCtD
Alosetron—Hypersensitivity—Cisplatin—esophageal cancer	0.00133	0.00426	CcSEcCtD
Alosetron—Infection—Capecitabine—esophageal cancer	0.00133	0.00424	CcSEcCtD
Alosetron—Asthenia—Cisplatin—esophageal cancer	0.0013	0.00415	CcSEcCtD
Alosetron—Skin disorder—Capecitabine—esophageal cancer	0.0013	0.00414	CcSEcCtD
Alosetron—Hyperhidrosis—Capecitabine—esophageal cancer	0.00129	0.00412	CcSEcCtD
Alosetron—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00128	0.00232	CbGpPWpGaD
Alosetron—CYP2E1—Metapathway biotransformation—GSTO1—esophageal cancer	0.00127	0.0023	CbGpPWpGaD
Alosetron—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00124	0.00224	CbGpPWpGaD
Alosetron—Alopecia—Methotrexate—esophageal cancer	0.00124	0.00395	CcSEcCtD
Alosetron—HTR3A—lung—esophageal cancer	0.00123	0.0628	CbGeAlD
Alosetron—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00122	0.00221	CbGpPWpGaD
Alosetron—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00122	0.00389	CcSEcCtD
Alosetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00121	0.00219	CbGpPWpGaD
Alosetron—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.00121	0.00218	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—ADH7—esophageal cancer	0.0012	0.00216	CbGpPWpGaD
Alosetron—CYP1A2—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00119	0.00215	CbGpPWpGaD
Alosetron—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.00117	0.00211	CbGpPWpGaD
Alosetron—Vomiting—Cisplatin—esophageal cancer	0.00115	0.00368	CcSEcCtD
Alosetron—Fatigue—Capecitabine—esophageal cancer	0.00115	0.00368	CcSEcCtD
Alosetron—Rash—Cisplatin—esophageal cancer	0.00114	0.00365	CcSEcCtD
Alosetron—Constipation—Capecitabine—esophageal cancer	0.00114	0.00365	CcSEcCtD
Alosetron—Pain—Capecitabine—esophageal cancer	0.00114	0.00365	CcSEcCtD
Alosetron—Dermatitis—Cisplatin—esophageal cancer	0.00114	0.00365	CcSEcCtD
Alosetron—Ill-defined disorder—Methotrexate—esophageal cancer	0.00113	0.00361	CcSEcCtD
Alosetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00112	0.00202	CbGpPWpGaD
Alosetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.00111	0.00201	CbGpPWpGaD
Alosetron—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.00111	0.00201	CbGpPWpGaD
Alosetron—Feeling abnormal—Capecitabine—esophageal cancer	0.0011	0.00352	CcSEcCtD
Alosetron—Malaise—Methotrexate—esophageal cancer	0.0011	0.00351	CcSEcCtD
Alosetron—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.0011	0.00198	CbGpPWpGaD
Alosetron—Nausea—Cisplatin—esophageal cancer	0.00108	0.00344	CcSEcCtD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—BAX—esophageal cancer	0.00107	0.00194	CbGpPWpGaD
Alosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00106	0.00192	CbGpPWpGaD
Alosetron—Cough—Methotrexate—esophageal cancer	0.00106	0.0034	CcSEcCtD
Alosetron—Urticaria—Capecitabine—esophageal cancer	0.00106	0.00339	CcSEcCtD
Alosetron—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.00106	0.00192	CbGpPWpGaD
Alosetron—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00106	0.00192	CbGpPWpGaD
Alosetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00105	0.00191	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—ALDH2—esophageal cancer	0.00105	0.0019	CbGpPWpGaD
Alosetron—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00105	0.0019	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—ADH1B—esophageal cancer	0.00105	0.0019	CbGpPWpGaD
Alosetron—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00104	0.00189	CbGpPWpGaD
Alosetron—Myalgia—Methotrexate—esophageal cancer	0.00104	0.00331	CcSEcCtD
Alosetron—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.00103	0.00187	CbGpPWpGaD
Alosetron—HTR3A—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.00103	0.00186	CbGpPWpGaD
Alosetron—CYP1A2—Phase II conjugation—GSTT1—esophageal cancer	0.00103	0.00186	CbGpPWpGaD
Alosetron—Discomfort—Methotrexate—esophageal cancer	0.00102	0.00327	CcSEcCtD
Alosetron—CYP1A2—Biological oxidations—ADH7—esophageal cancer	0.00102	0.00185	CbGpPWpGaD
Alosetron—Confusional state—Methotrexate—esophageal cancer	0.001	0.0032	CcSEcCtD
Alosetron—CYP2E1—Biological oxidations—GSTT1—esophageal cancer	0.000999	0.00181	CbGpPWpGaD
Alosetron—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.000997	0.0018	CbGpPWpGaD
Alosetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000991	0.00179	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—CYP2A6—esophageal cancer	0.000987	0.00179	CbGpPWpGaD
Alosetron—Infection—Methotrexate—esophageal cancer	0.000987	0.00316	CcSEcCtD
Alosetron—Hypersensitivity—Capecitabine—esophageal cancer	0.000983	0.00314	CcSEcCtD
Alosetron—CYP2C9—Biological oxidations—CYP26A1—esophageal cancer	0.000975	0.00176	CbGpPWpGaD
Alosetron—Skin disorder—Methotrexate—esophageal cancer	0.000965	0.00308	CcSEcCtD
Alosetron—CYP2C9—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000961	0.00174	CbGpPWpGaD
Alosetron—Hyperhidrosis—Methotrexate—esophageal cancer	0.00096	0.00307	CcSEcCtD
Alosetron—Asthenia—Capecitabine—esophageal cancer	0.000958	0.00306	CcSEcCtD
Alosetron—CYP2E1—Biological oxidations—PTGS1—esophageal cancer	0.000936	0.00169	CbGpPWpGaD
Alosetron—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000917	0.00166	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—GSTO1—esophageal cancer	0.000906	0.00164	CbGpPWpGaD
Alosetron—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000905	0.00289	CcSEcCtD
Alosetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.0009	0.00163	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—ADH1B—esophageal cancer	0.000896	0.00162	CbGpPWpGaD
Alosetron—CYP2C9—Metapathway biotransformation—GSTO1—esophageal cancer	0.000894	0.00162	CbGpPWpGaD
Alosetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000862	0.00156	CbGpPWpGaD
Alosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000857	0.00155	CbGpPWpGaD
Alosetron—Fatigue—Methotrexate—esophageal cancer	0.000857	0.00274	CcSEcCtD
Alosetron—Pain—Methotrexate—esophageal cancer	0.00085	0.00272	CcSEcCtD
Alosetron—Vomiting—Capecitabine—esophageal cancer	0.000849	0.00271	CcSEcCtD
Alosetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000847	0.00153	CbGpPWpGaD
Alosetron—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000846	0.00153	CbGpPWpGaD
Alosetron—Rash—Capecitabine—esophageal cancer	0.000841	0.00269	CcSEcCtD
Alosetron—Dermatitis—Capecitabine—esophageal cancer	0.000841	0.00269	CcSEcCtD
Alosetron—Headache—Capecitabine—esophageal cancer	0.000836	0.00267	CcSEcCtD
Alosetron—CYP1A2—Biological oxidations—CYP26A1—esophageal cancer	0.000833	0.00151	CbGpPWpGaD
Alosetron—CYP1A2—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000821	0.00149	CbGpPWpGaD
Alosetron—Feeling abnormal—Methotrexate—esophageal cancer	0.000819	0.00262	CcSEcCtD
Alosetron—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000817	0.00148	CbGpPWpGaD
Alosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000806	0.00146	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—CYP1B1—esophageal cancer	0.000796	0.00144	CbGpPWpGaD
Alosetron—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000795	0.00144	CbGpPWpGaD
Alosetron—HTR3A—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000794	0.00144	CbGpPWpGaD
Alosetron—Nausea—Capecitabine—esophageal cancer	0.000793	0.00253	CcSEcCtD
Alosetron—Urticaria—Methotrexate—esophageal cancer	0.000789	0.00252	CcSEcCtD
Alosetron—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000788	0.00143	CbGpPWpGaD
Alosetron—CYP2E1—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000785	0.00142	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—GSTO1—esophageal cancer	0.000774	0.0014	CbGpPWpGaD
Alosetron—CYP1A2—Metapathway biotransformation—GSTO1—esophageal cancer	0.000764	0.00138	CbGpPWpGaD
Alosetron—HTR3A—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000762	0.00138	CbGpPWpGaD
Alosetron—CYP1A2—digestive system—esophageal cancer	0.000761	0.0388	CbGeAlD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—RB1—esophageal cancer	0.000753	0.00136	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—CYP19A1—esophageal cancer	0.000748	0.00135	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	0.000739	0.00134	CbGpPWpGaD
Alosetron—CYP2E1—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000738	0.00134	CbGpPWpGaD
Alosetron—Hypersensitivity—Methotrexate—esophageal cancer	0.000732	0.00234	CcSEcCtD
Alosetron—CYP2C9—digestive system—esophageal cancer	0.000723	0.0368	CbGeAlD
Alosetron—Asthenia—Methotrexate—esophageal cancer	0.000713	0.00228	CcSEcCtD
Alosetron—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	0.000702	0.00127	CbGpPWpGaD
Alosetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000695	0.00126	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	0.000694	0.00126	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000691	0.00125	CbGpPWpGaD
Alosetron—CYP2E1—digestive system—esophageal cancer	0.000685	0.0349	CbGeAlD
Alosetron—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000678	0.00123	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	0.000658	0.00119	CbGpPWpGaD
Alosetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000653	0.00118	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000643	0.00116	CbGpPWpGaD
Alosetron—CYP1A2—lung—esophageal cancer	0.000636	0.0324	CbGeAlD
Alosetron—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000634	0.00115	CbGpPWpGaD
Alosetron—Vomiting—Methotrexate—esophageal cancer	0.000632	0.00202	CcSEcCtD
Alosetron—CYP1A2—Biological oxidations—ALDH2—esophageal cancer	0.000631	0.00114	CbGpPWpGaD
Alosetron—Rash—Methotrexate—esophageal cancer	0.000626	0.002	CcSEcCtD
Alosetron—Dermatitis—Methotrexate—esophageal cancer	0.000626	0.002	CcSEcCtD
Alosetron—Headache—Methotrexate—esophageal cancer	0.000622	0.00199	CcSEcCtD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—esophageal cancer	0.000619	0.00112	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—GSTT1—esophageal cancer	0.0006	0.00109	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000598	0.00108	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—CYP2A6—esophageal cancer	0.000593	0.00107	CbGpPWpGaD
Alosetron—Nausea—Methotrexate—esophageal cancer	0.00059	0.00189	CcSEcCtD
Alosetron—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000589	0.00107	CbGpPWpGaD
Alosetron—CYP1A2—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000579	0.00105	CbGpPWpGaD
Alosetron—CYP2E1—lung—esophageal cancer	0.000572	0.0291	CbGeAlD
Alosetron—CYP1A2—Biological oxidations—PTGS1—esophageal cancer	0.000563	0.00102	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	0.00056	0.00101	CbGpPWpGaD
Alosetron—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000552	0.000999	CbGpPWpGaD
Alosetron—CYP3A4—digestive system—esophageal cancer	0.000551	0.0281	CbGeAlD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—esophageal cancer	0.000541	0.000979	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.00054	0.000977	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	0.000526	0.000952	CbGpPWpGaD
Alosetron—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000519	0.000939	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—EP300—esophageal cancer	0.000515	0.000932	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—esophageal cancer	0.000515	0.000932	CbGpPWpGaD
Alosetron—HTR3A—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000509	0.000922	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000487	0.000881	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—CYP1B1—esophageal cancer	0.000478	0.000866	CbGpPWpGaD
Alosetron—CYP1A2—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000472	0.000854	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000463	0.000838	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000461	0.000835	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000458	0.000829	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—CYP19A1—esophageal cancer	0.00045	0.000814	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—MYC—esophageal cancer	0.000449	0.000812	CbGpPWpGaD
Alosetron—CYP1A2—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000444	0.000803	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—esophageal cancer	0.000439	0.000794	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—esophageal cancer	0.000439	0.000794	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000434	0.000786	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—BLVRB—esophageal cancer	0.000402	0.000727	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—SLC52A3—esophageal cancer	0.000402	0.000727	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000369	0.000668	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000365	0.00066	CbGpPWpGaD
Alosetron—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000364	0.000659	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000347	0.000628	CbGpPWpGaD
Alosetron—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000342	0.000619	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CA1—esophageal cancer	0.000342	0.000619	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—SLC10A2—esophageal cancer	0.000342	0.000619	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000318	0.000576	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CA2—esophageal cancer	0.000313	0.000566	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000312	0.000564	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ADH7—esophageal cancer	0.000291	0.000526	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PLCE1—esophageal cancer	0.000291	0.000526	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—SLC52A3—esophageal cancer	0.000283	0.000512	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—BLVRB—esophageal cancer	0.000283	0.000512	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000272	0.000492	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ADH1B—esophageal cancer	0.000255	0.000461	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000253	0.000457	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—TYMP—esophageal cancer	0.000244	0.000441	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—SLC52A3—esophageal cancer	0.000242	0.000437	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—BLVRB—esophageal cancer	0.000242	0.000437	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CA1—esophageal cancer	0.00024	0.000435	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—SLC10A2—esophageal cancer	0.00024	0.000435	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CYP26A1—esophageal cancer	0.000237	0.000429	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ALOX15—esophageal cancer	0.000231	0.000418	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GSTO1—esophageal cancer	0.00022	0.000399	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—TPI1—esophageal cancer	0.00022	0.000399	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CA2—esophageal cancer	0.00022	0.000398	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000216	0.000391	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000215	0.000389	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ALDOB—esophageal cancer	0.000211	0.000382	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CA1—esophageal cancer	0.000205	0.000372	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—SLC10A2—esophageal cancer	0.000205	0.000372	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PLCE1—esophageal cancer	0.000204	0.00037	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ADH7—esophageal cancer	0.000204	0.00037	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GAPDH—esophageal cancer	0.000203	0.000368	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000202	0.000366	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CRABP1—esophageal cancer	0.000201	0.000365	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GNG7—esophageal cancer	0.000192	0.000347	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CA2—esophageal cancer	0.000188	0.00034	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.000186	0.000337	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.000186	0.000337	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000184	0.000332	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ALDH2—esophageal cancer	0.00018	0.000325	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ADH1B—esophageal cancer	0.000179	0.000324	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ADH7—esophageal cancer	0.000175	0.000316	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PLCE1—esophageal cancer	0.000175	0.000316	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000173	0.000313	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—TYMP—esophageal cancer	0.000171	0.00031	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GSTT1—esophageal cancer	0.000171	0.000309	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CYP2A6—esophageal cancer	0.000169	0.000305	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP26A1—esophageal cancer	0.000167	0.000302	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ALOX15—esophageal cancer	0.000162	0.000294	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ENO1—esophageal cancer	0.00016	0.00029	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PTGS1—esophageal cancer	0.00016	0.00029	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000159	0.000287	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CA1—esophageal cancer	0.000159	0.000287	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PSME2—esophageal cancer	0.000158	0.000285	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PSME1—esophageal cancer	0.000158	0.000285	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTO1—esophageal cancer	0.000155	0.00028	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—TPI1—esophageal cancer	0.000155	0.00028	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ADH1B—esophageal cancer	0.000153	0.000277	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ALDOB—esophageal cancer	0.000149	0.000269	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—TYMP—esophageal cancer	0.000146	0.000265	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CA2—esophageal cancer	0.000145	0.000262	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GAPDH—esophageal cancer	0.000143	0.000259	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CYP26A1—esophageal cancer	0.000142	0.000258	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CRABP1—esophageal cancer	0.000142	0.000256	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ALOX15—esophageal cancer	0.000139	0.000251	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CYP1B1—esophageal cancer	0.000136	0.000246	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ADH7—esophageal cancer	0.000135	0.000244	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PLCE1—esophageal cancer	0.000135	0.000244	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GNG7—esophageal cancer	0.000135	0.000244	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTO1—esophageal cancer	0.000132	0.00024	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—TPI1—esophageal cancer	0.000132	0.00024	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CYP19A1—esophageal cancer	0.000128	0.000232	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ALDOB—esophageal cancer	0.000127	0.00023	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ALDH2—esophageal cancer	0.000126	0.000229	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GAPDH—esophageal cancer	0.000122	0.000221	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CRABP1—esophageal cancer	0.000121	0.000219	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTT1—esophageal cancer	0.00012	0.000217	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP2A6—esophageal cancer	0.000119	0.000215	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000118	0.000214	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ADH1B—esophageal cancer	0.000118	0.000214	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—HMOX1—esophageal cancer	0.000117	0.000211	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GNG7—esophageal cancer	0.000115	0.000208	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—TYMP—esophageal cancer	0.000113	0.000204	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ENO1—esophageal cancer	0.000113	0.000204	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PTGS1—esophageal cancer	0.000113	0.000204	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ABCB1—esophageal cancer	0.000112	0.000203	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PSME2—esophageal cancer	0.000111	0.000201	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PSME1—esophageal cancer	0.000111	0.000201	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP26A1—esophageal cancer	0.00011	0.000199	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ALDH2—esophageal cancer	0.000108	0.000195	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ALOX15—esophageal cancer	0.000107	0.000194	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTT1—esophageal cancer	0.000103	0.000186	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—TPI1—esophageal cancer	0.000102	0.000185	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTO1—esophageal cancer	0.000102	0.000185	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CYP2A6—esophageal cancer	0.000101	0.000184	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	0.000101	0.000183	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ALDOB—esophageal cancer	9.8e-05	0.000177	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	9.69e-05	0.000175	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ENO1—esophageal cancer	9.62e-05	0.000174	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PTGS1—esophageal cancer	9.62e-05	0.000174	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP1B1—esophageal cancer	9.57e-05	0.000173	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PSME1—esophageal cancer	9.48e-05	0.000172	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PSME2—esophageal cancer	9.48e-05	0.000172	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GAPDH—esophageal cancer	9.43e-05	0.000171	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CRABP1—esophageal cancer	9.35e-05	0.000169	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP19A1—esophageal cancer	9e-05	0.000163	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GNG7—esophageal cancer	8.89e-05	0.000161	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ALDH2—esophageal cancer	8.33e-05	0.000151	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.28e-05	0.00015	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—HMOX1—esophageal cancer	8.21e-05	0.000149	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CYP1B1—esophageal cancer	8.18e-05	0.000148	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	8.06e-05	0.000146	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTT1—esophageal cancer	7.92e-05	0.000143	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ABCB1—esophageal cancer	7.88e-05	0.000143	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP2A6—esophageal cancer	7.83e-05	0.000142	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CYP19A1—esophageal cancer	7.69e-05	0.000139	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CREBBP—esophageal cancer	7.49e-05	0.000136	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PTGS1—esophageal cancer	7.42e-05	0.000134	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ENO1—esophageal cancer	7.42e-05	0.000134	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PSME2—esophageal cancer	7.32e-05	0.000132	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PSME1—esophageal cancer	7.32e-05	0.000132	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—HMOX1—esophageal cancer	7.02e-05	0.000127	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6.88e-05	0.000125	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ABCB1—esophageal cancer	6.74e-05	0.000122	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—NOS3—esophageal cancer	6.7e-05	0.000121	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP1B1—esophageal cancer	6.31e-05	0.000114	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PTGS2—esophageal cancer	6.13e-05	0.000111	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.96e-05	0.000108	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP19A1—esophageal cancer	5.94e-05	0.000107	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—HMOX1—esophageal cancer	5.42e-05	9.8e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CREBBP—esophageal cancer	5.27e-05	9.53e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ABCB1—esophageal cancer	5.2e-05	9.41e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—EP300—esophageal cancer	5.1e-05	9.23e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.09e-05	9.22e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—NOS3—esophageal cancer	4.72e-05	8.54e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CREBBP—esophageal cancer	4.5e-05	8.15e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PTGS2—esophageal cancer	4.31e-05	7.81e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—NOS3—esophageal cancer	4.03e-05	7.29e-05	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—PIK3CA—esophageal cancer	3.77e-05	6.83e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PTGS2—esophageal cancer	3.69e-05	6.67e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—EP300—esophageal cancer	3.59e-05	6.49e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CREBBP—esophageal cancer	3.47e-05	6.29e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—NOS3—esophageal cancer	3.11e-05	5.63e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—EP300—esophageal cancer	3.07e-05	5.55e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.85e-05	5.15e-05	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—PIK3CA—esophageal cancer	2.65e-05	4.8e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—EP300—esophageal cancer	2.37e-05	4.28e-05	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—PIK3CA—esophageal cancer	2.27e-05	4.1e-05	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.75e-05	3.17e-05	CbGpPWpGaD
